Clinical Development of Cationic Antimicrobial Peptides: From Natural to Novel Antibiotics
The DOI matches its Crossref record.
Abstract
Over the past decade, levels of bacterial resistance to antibiotics have risen dramatically and ”superbugs“ resistant to most or all available agents have appeared in the clinic. Thus there is a growing need to discover and introduce new drugs. One potential source of novel antibiotics is the cationic antimicrobial peptides, which have been isolated from most living entities as components of their non-specific defenses against infectious organisms. Based on these natural templates, scores of structurally diverse antimicrobial cationic peptides have been designed, manufactured both chemically and biologically, and tested for activity against specific pathogens. A few of these peptide antibiotics have entered clinical trials to date, with mixed success. However, their diverse portfolio of structures, activity spectra, biological activities, and modes of action, provide substantial potential. Keywords: Cationic Antimicrobial Peptides, Cationic peptides, Antibiotics, Burkholderia, COMBINATORIAL LIBRARIES, Lipopolysaccharide, Methicillin resistant Staphylococcus aureus, Vancomycin resistant Entrococcus
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
Brogden, K. A. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1098 · Cited by 5,829
“Antimicrobial peptides are recognized as a possible source of pharmaceuticals for the treatment of antibiotic-resistant bacterial infections or septic shoc”
BackgroundJenssen, H., Hamill, P., & Hancock, R. E. W. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.00056-05 · Cited by 2,518
Self-citationAntagonistic activities of lactobacilli and bifidobacteria against microbial pathogens
Servin, A. L. (2004) · FEMS Microbiology Reviews · doi:10.1016/j.femsre.2004.01.003 · Cited by 1,236
Antibacterial peptides: basic facts and emerging concepts
Boman, H. G. (2003) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01228.x · Cited by 1,158
Gombart, A. F., Borregaard, N., & Koeffler, H. P. (2005) · The FASEB Journal · doi:10.1096/fj.04-3284com · Cited by 1,136
Antimicrobial peptides: mechanism of action, activity and clinical potential
Zhang, Q.-Y., Yan, Z.-B., Meng, Y.-M., Hong, X.-Y., Shao, G., Ma, J.-J., Cheng, X.-R., Liu, J., Kang, J., & Fu, C.-Y. (2021) · Military Medical Research · doi:10.1186/s40779-021-00343-2 · Cited by 1,065
APD: the Antimicrobial Peptide Database
Wang, Z. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh025 · Cited by 808
Alternative mechanisms of action of cationic antimicrobial peptides on bacteria
Hale, J. D., & Hancock, R. E. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.6.951 · Cited by 549
Self-citationXiao, X., Wang, P., Lin, W.-Z., Jia, J.-H., & Chou, K.-C. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.01.019 · Cited by 547
Mookherjee, N., & Hancock, R. E. W. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6475-6 · Cited by 462
Self-citationSustainable aquaculture requires environmental‐friendly treatment strategies for fish diseases
Lieke, T., Meinelt, T., Hoseinifar, S. H., Pan, B., Straus, D. L., & Steinberg, C. E. W. (2020) · Reviews in Aquaculture · doi:10.1111/raq.12365 · Cited by 363
Induction of cathelicidin in normal and CF bronchial epithelial cells by 1,25-dihydroxyvitamin D3
Yim, S., Dhawan, P., Ragunath, C., Christakos, S., & Diamond, G. (2007) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2007.03.003 · Cited by 347
Kazemzadeh-Narbat, M., Kindrachuk, J., Duan, K., Jenssen, H., Hancock, R. E. W., & Wang, R. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.08.035 · Cited by 343
Self-citationWill new generations of modified antimicrobial peptides improve their potential as pharmaceuticals?
Brogden, N. K., & Brogden, K. A. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.05.004 · Cited by 300
Analysis and prediction of antibacterial peptides
Lata, S., Sharma, B., & Raghava, G. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-263 · Cited by 296
Antimicrobial Peptides: Versatile Biological Properties
Pushpanathan, M., Gunasekaran, P., & Rajendhran, J. (2013) · International Journal of Peptides · doi:10.1155/2013/675391 · Cited by 292
Peptide design for antimicrobial and immunomodulatory applications
Haney, E. F., & Hancock, R. E. W. (2013) · Peptide Science · doi:10.1002/bip.22250 · Cited by 291
Self-citationRelevance of microbial coculture fermentations in biotechnology
Bader, J., Mast‐Gerlach, E., Popović, M. K., Bajpai, R., & Stahl, U. (2010) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2009.04659.x · Cited by 287
AntiBP2: improved version of antibacterial peptide prediction
Lata, S., Mishra, N. K., & Raghava, G. P. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-s1-s19 · Cited by 283
Host defence peptides from invertebrates – emerging antimicrobial strategies
Hancock, R. E. W., Brown, K. L., & Mookherjee, N. (2006) · Immunobiology · doi:10.1016/j.imbio.2005.10.017 · Cited by 282
Self-citationAntimicrobial peptides: promising compounds against pathogenic microorganisms
Cruz, J., Ortiz, C., Guzmán, F., Fernández-Lafuente, R., & Torres, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140217110155 · Cited by 166
Metadata
- Authors
- Hancock, R., & Patrzykat, A.
- Venue
- Current Drug Target -Infectious Disorders
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2002-03-01
- Volume
- 2
- Issue
- 1
- Pages
- 79-83
- ISSN
- 1568-0053 (ISSN-L)
- OpenAlex
- W2166290770
- Cited by
- 365
- References
- 0
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.